The EDGE

Is there consensus on consensus?

J-J Kiladjian and R P Gale

Leukemia 2016 30: 1229; advance online publication, May 10, 2016; 10.1038/leu.2016.38

Original Articles

ACUTE MYELOID LEUKEMIA

Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia

U Krug, W E Berdel, R P Gale, C Haferlach, S Schnittger, C Müller-Tidow, J Braess, K Spiekermann, P Staib, D Beelen, H Serve, C Schliemann, M Stelljes, L Balleisen, G Maschmeyer, A Grüneisen, H Eimermacher, A Giagounidis, H Rasche, R Hehlmann, E Lengfelder, E Thiel, A Reichle, C Aul, W-D Ludwig, W Kern, T Haferlach, W Köpcke, D Görlich, M C Sauerland, A Heinecke, B J Wörmann, W Hiddemann and T Büchner for the German Acute Myeloid Leukemia Cooperative Group (AMLCG)

Leukemia 2016 30: 1230-1236; advance online publication, February 9, 2016; 10.1038/leu.2016.25

GFI1 as a novel prognostic and therapeutic factor for AML/MDS

J M Hönes, L Botezatu, A Helness, C Vadnais, L Vassen, F Robert, S M Hergenhan, A Thivakaran, J Schütte, Y S Al-Matary, R F Lams, J Fraszscak, H Makishima, T Radivoyevitch, B Przychodzen, S V da Conceição Castro, A Görgens, B Giebel, L Klein-Hitpass, K Lennartz, M Heuser, C Thiede, G Ehninger, U Dührsen, J P Maciejewski, T Möröy and C Khandanpour

Leukemia 2016 30: 1237-1245; advance online publication, February 5, 2016; 10.1038/leu.2016.11

ACUTE LYMPHOBLASTIC LEUKEMIA

Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition

S Köhrer, O Havranek, F Seyfried, C Hurtz, G P Coffey, E Kim, E ten Hacken, U Jäger, K Vanura, S O'Brien, D A Thomas, H Kantarjian, D Ghosh, Z Wang, M Zhang, W Ma, H Jumaa, K-M Debatin, M Müschen, L H Meyer, R E Davis and J A Burger

Leukemia 2016 30: 1246-1254; advance online publication, February 5, 2016; 10.1038/leu.2016.9

CHRONIC MYELOGENOUS LEUKEMIA

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV OPEN

M B Miranda, M Lauseker, M-P Kraus, U Proetel, B Hanfstein, A Fabarius, G M Baerlocher, D Heim, D K Hossfeld, H-J Kolb, S W Krause, C Nerl, T H Brümmendorf, W Verbeek, A A Fauser, O Prümmer, K Neben, U Hess, R Mahlberg, C Plöger, M Flasshove, B Rendenbach, W-K Hofmann, M C Müller, M Pfirrmann, A Hochhaus, J Hasford, R Hehlmann and S Saußele

Leukemia 2016 30: 1255-1262; advance online publication, February 9, 2016; 10.1038/leu.2016.20

TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy

E Nievergall, J Reynolds, C H Kok, D B Watkins, M Biondo, S J Busfield, G Vairo, K Fuller, W N Erber, T Sadras, R Grose, D T Yeung, A F Lopez, D K Hiwase, T P Hughes and D L White

Leukemia 2016 30: 1263-1272; advance online publication, February 22, 2016; 10.1038/leu.2016.34

High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-X_L in chronic myeloid leukemia OPEN

C M Lucas, M Milani, M Butterworth, N Carmell, L J Scott, R E Clark, G M Cohen and S Varadarajan

Leukemia 2016 30: 1273-1281; advance online publication, February 29, 2016; 10.1038/leu.2016.42

Aberrant activation of CaMKIIγ accelerates chronic myeloid leukemia blast crisis

Y Gu, W Zheng, J Zhang, X Gan, X Ma, Z Meng, T Chen, X Lu, Z Wu, W Huang and R Xu

Leukemia 2016 30: 1282-1289; advance online publication, March 8, 2016; 10.1038/leu.2016.53

CHRONIC LYMPHOCYTIC LEUKEMIA

Lysosomotropic agents selectively target chronic lymphocytic leukemia cells due to altered sphingolipid metabolism

R F Dielschneider, H Eisenstat, S Mi, J M Curtis, W Xiao, J B Johnston and S B Gibson

Leukemia 2016 30: 1290-1300; advance online publication, February 23, 2015; 10.1038/leu.2016.4

Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive disease OPEN

M J J Rose-Zerilli, J Gibson, J Wang, W Tapper, Z Davis, H Parker, M Larrayoz, H McCarthy, R Walewska, J Forster, A Gardiner, A J Steele, C Chelala, S Ennis, A Collins, C C Oakes, D G Oscier and J C Strefford

Leukemia 2016 30: 1301-1310; advance online publication, February 5, 2016; 10.1038/leu.2016.10

LYMPHOMA

JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma OPEN

M-L Nairismägi, J Tan, J Q Lim, S Nagarajan, C C Y Ng, V Rajasegaran, D Huang, W K Lim, Y Laurensia, G C Wijaya, Z M Li, I Cutcutache, W L Pang, S Thangaraju, J Ha, L P Khoo, S T Chin, S Dey, G Poore, L H C Tan, H K M Koh, K Sabai, H-L Rao, K L Chuah, Y-H Ho, S-B Ng, S-S Chuang, F Zhang, Y-H Liu, T Pongpruttipan, Y H Ko, P-L Cheah, N Karim, W-J Chng, T Tang, M Tao, K Tay, M Farid, R Quek, S G Rozen, P Tan, B T Teh, S T Lim, S-Y Tan and C K Ong

Leukemia 2016 30: 1311-1319; advance online publication, February 8, 2016; 10.1038/leu.2016.13

MULTIPLE MYELOMA, GAMMOPATHIES

A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma

A Larocca, S Bringhen, M T Petrucci, S Oliva, A P Falcone, T Caravita, O Villani, G Benevolo, A M Liberati, F Morabito, V Montefusco, R Passera, L De Rosa, P Omedé, I D Vincelli, S Spada, A M Carella, E Ponticelli, D Derudas, M Genuardi, T Guglielmelli, C Nozzoli, E Aghemo, L De Paoli, C Conticello, C Musolino, M Offidani, M Boccadoro, P Sonneveld and A Palumbo

Leukemia 2016 30: 1320-1326; advance online publication, February 22, 2016; 10.1038/leu.2016.36

STEM CELL BIOLOGY

MIM regulates the trafficking of bone marrow cells via modulating surface expression of CXCR4

T Zhan, C Cao, L Li, N Gu, C I Civin and X Zhan

Leukemia 2016 30: 1327-1334; advance online publication, February 29, 2016; 10.1038/leu.2016.39

MOLECULAR TARGETS FOR THERAPY

Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras

J Akutagawa, T Q Huang, I Epstein, T Chang, M Quirindongo-Crespo, C L Cottonham, M Dail, B S Slusher, L S Friedman, D Sampath and B S Braun

Leukemia 2016 30: 1335-1343; advance online publication, February 12, 2016; 10.1038/leu.2016.14

IMMUNOTHERAPY

Proteogenomic-based discovery of minor histocompatibility antigens with suitable features for immunotherapy of hematologic cancers

D P Granados, A Rodenbrock, J-P Laverdure, C Côté, O Caron-Lizotte, C Carli, H Pearson, V Janelle, C Durette, E Bonneil, D C Roy, J-S Delisle, S Lemieux, P Thibault and C Perreault

Leukemia 2016 30: 1344-1354; advance online publication, February 9, 2016; 10.1038/leu.2016.22

High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity

R C Lynn, Y Feng, K Schutsky, M Poussin, A Kalota, D S Dimitrov and D J Powell Jr

Leukemia 2016 30: 1355-1364; advance online publication, February 22, 2016; 10.1038/leu.2016.35

TRANSCRIPTIONAL CONTROL AND SIGNAL TRANSDUCTION, CELL CYCLE

The TCA cycle transferase DLST is important for MYC-mediated leukemogenesis

N M Anderson, D Li, H L Peng, F J F Laroche, M R Mansour, E Gjini, M Aioub, D J Helman, J E Roderick, T Cheng, I Harrold, Y Samaha, L Meng, A Amsterdam, D S Neuberg, T T Denton, T Sanda, M A Kelliher, A Singh, A T Look and H Feng

Leukemia 2016 30: 1365-1374; advance online publication, February 15, 2016; 10.1038/leu.2016.26

PU.1 cooperates with IRF4 and IRF8 to suppress pre-B-cell leukemia

S H M Pang, M Minnich, P Gangatirkar, Z Zheng, A Ebert, G Song, R A Dickins, L M Corcoran, C G Mullighan, M Busslinger, N D Huntington, S L Nutt and S Carotta

Leukemia 2016 30: 1375-1387; advance online publication, March 2, 2016; 10.1038/leu.2016.27

DNMT3A^R882H mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice

L Scourzic, L Couronné, M T Pedersen, V Della Valle, M Diop, E Mylonas, J Calvo, E Mouly, C K Lopez, N Martin, M Fontenay, A Bender, S Guibert, P Dubreuil, P Dessen, N Droin, F Pflumio, M Weber, P Gaulard, K Helin, T Mercher and O A Bernard

Leukemia 2016 30: 1388-1398; advance online publication, February 15, 2016; 10.1038/leu.2016.29

Letters to the Editor

A novel Lin−CD34+CD38− integrin α2− bipotential megakaryocyte–erythrocyte progenitor population in the human bone marrow OPEN

W M Wong, M Dolinska, M Sigvardsson, M Ekblom and H Qian

Leukemia 2016 30: 1399-1402; advance online publication, October 26, 2015; 10.1038/leu.2015.300

Delayed diagnosis leading to accelerated-phase chronic eosinophilic leukemia due to a cytogenetically cryptic, imatinib-responsive TNIP1–PDFGRB fusion gene

D M Ross, H K Altamura, C N Hahn, M Nicola, A L Yeoman, M R Holloway, J Geoghegan, J Feng, A W Schreiber, S Branford, S Moore and H S Scott

Leukemia 2016 30: 1402-1405; advance online publication, October 27, 2015; 10.1038/leu.2015.301

Novel TKI-resistant BCR-ABL1 gatekeeper residue mutations retain in vitro sensitivity to axitinib

E A Lasater, E S Massi, A Stecula, J Politi, S K Tan, C C Smith, M Gunthorpe, J P Holmes, F Chehab, A Sali and N P Shah

Leukemia 2016 30: 1405-1409; advance online publication, October 29, 2015; 10.1038/leu.2015.303

CD4+ T cells, but not non-classical monocytes, are dispensable for the development of chronic lymphocytic leukemia in the TCL1-tg murine model OPEN

T Kocher, D Asslaber, N Zaborsky, S Flenady, U Denk, P Reinthaler, M Ablinger, R Geisberger, J W Bauer, M Seiffert, T N Hartmann, R Greil, A Egle and J Piñón Hofbauer

Leukemia 2016 30: 1409-1413; advance online publication, November 2, 2015; 10.1038/leu.2015.307

Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis OPEN

S Verstovsek, E Atallah, J Mascarenhas, H Sun, M Montgomery, V Gupta, R Mesa and J Gotlib

Leukemia 2016 30: 1413-1415; advance online publication, November 3, 2015; 10.1038/leu.2015.310

Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine

J Desoutter, J Gay, C Berthon, L Ades, B Gruson, S Geffroy, I Plantier, A Marceau, N Helevaut, J Fernandes, M Bemba, L Stalnikiewicz, C Frimat, J Labreuche, O Nibourel, C Roumier, M Figeac, P Fenaux, B Quesnel, A Renneville, A Duhamel and C Preudhomme

Leukemia 2016 30: 1416-1418; advance online publication, November 19, 2015; 10.1038/leu.2015.314

Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia OPEN

M S Zabriskie, C A Eide, D Yan, N A Vellore, A D Pomicter, S L Savage, B J Druker, M W Deininger and T O'Hare

Leukemia 2016 30: 1418-1421; advance online publication, November 19, 2015; 10.1038/leu.2015.318

Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone

G E Nybakken, J Canaani, D Roy, J D Morrissette, C D Watt, N P Shah, C C Smith, A Bagg, M Carroll and A E Perl

Leukemia 2016 30: 1422-1425; advance online publication, November 20, 2015; 10.1038/leu.2015.320

Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group

D A Eichenauer, H Goergen, A Plütschow, D Wongso, K Behringer, S Kreissl, I Thielen, T Halbsguth, P J Bröckelmann, M Fuchs, B Böll, B von Tresckow, P Borchmann and A Engert

Leukemia 2016 30: 1425-1427; advance online publication, November 20, 2015; 10.1038/leu.2015.321

Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials

E Hoster, C H Geisler, J Doorduijn, B van der Holt, J Walewski, J Bloehdorn, V Ribrag, G Salles, M Hallek, C Pott, M Szymczyk, A Kolstad, A Laurell, R Räty, M Jerkeman, M van't Veer, J C Kluin-Nelemans, W Klapper, M Unterhalt, M Dreyling and O Hermine for the European Mantle Cell Lymphoma Network

Leukemia 2016 30: 1428-1430; advance online publication, November 24, 2015; 10.1038/leu.2015.322

Axl activates fibroblast growth factor receptor pathway to potentiate survival signals in B-cell chronic lymphocytic leukemia cells

S Sinha, J Boysen, M Nelson, S L Warner, D Bearss, N E Kay and A K Ghosh

Leukemia 2016 30: 1431-1436; advance online publication, November 24, 2015; 10.1038/leu.2015.323

Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II in leukemia OPEN

C Song, X Pan, Z Ge, C Gowda, Y Ding, H Li, Z Li, G Yochum, M Muschen, Q Li, K J Payne and S Dovat

Leukemia 2016 30: 1436-1440; advance online publication, December 7, 2015; 10.1038/leu.2015.331

A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients

M Gentile, T D Shanafelt, G Cutrona, S Molica, G Tripepi, I Alvarez, F R Mauro, N Di Renzo, F Di Raimondo, I Vincelli, K Todoerti, S Matis, C Musolino, S Fabris, E Vigna, L Levato, S Zupo, F Angrilli, U Consoli, G Festini, G Longo, A Cortelezzi, A Arcari, M Federico, D Mannina, A G Recchia, A Neri, N E Kay, M Ferrarini and F Morabito

Leukemia 2016 30: 1440-1443; advance online publication, December 9, 2015; 10.1038/leu.2015.333

Clinical prevalence (diagnosed cases) of monoclonal gammopathy of undetermined significance in the US: estimating the burden on health care

R S Go, K M Swanson, L R Sangaralingham, E B Habermann and N D Shah

Leukemia 2016 30: 1443-1446; advance online publication, December 9, 2015; 10.1038/leu.2015.336

Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma? OPEN

C Pawlyn, L Fowkes, S Otero, J R Jones, K D Boyd, F E Davies, G J Morgan, D J Collins, B Sharma, A Riddell, M F Kaiser and C Messiou

Leukemia 2016 30: 1446-1448; advance online publication, December 9, 2015; 10.1038/leu.2015.338

Correspondence

Population-based analyses among 184 patients diagnosed with large granular lymphocyte leukemia in the Netherlands between 2001 and 2013

A G Dinmohamed, M Brink, O Visser and M Jongen-Lavrencic

Leukemia 2016 30: 1449-1451; advance online publication, April 8, 2016; 10.1038/leu.2016.68

Retraction

Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells

C Yu, G Dasmahapatra, P Dent and S Grant

Leukemia 2016 30: 1452; advance online publication, April 8, 2016; 10.1038/leu.2016.7